LGM
APGE icon

Logos Global Management’s Apogee Therapeutics APGE Stock Holding History

Logos Global Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-300,000
Closed -$13.6M – 41
2024
Q4 		$13.6M Buy
+300,000
New +$15.3M 1.59% 23

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Logos Global Management's APGE Position: Q1 2025 in Review

Logos Global Management sold out of Apogee Therapeutics (APGE) in Q1 2025, closing a stake of 300,000 shares — an estimated $13.6M sold.

Logos Global Management first reported a position in APGE in Q4 2024 and held it in 1 quarter. The position peaked at $13.6M in Q4 2024. 168 funds tracked by Wall St. Rank hold APGE as of Q1 2025.

  • Logos Global Management reported no remaining Apogee Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Logos Global Management sold 300,000 Apogee Therapeutics shares in Q1 2025, an estimated $13.6M.
  • Logos Global Management first reported a position in Apogee Therapeutics in Q4 2024 and held it in 1 quarter.
  • Logos Global Management's Apogee Therapeutics position peaked at $13.6M in Q4 2024.
  • 168 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2025.

Based on Logos Global Management's 13F filing for Q1 2025, filed 15 May 2025.